ICCC logo

IMMUCELL CORP

ICCCNASDAQ
πŸ† #3977 by market capUS Equity
$10.42β–Ό $0.09 (βˆ’0.81%)
Latest quote
πŸ””
Track ICCC
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.8%
7dβ–Ό 1.7%
14dβ–Ό 2.6%
30dβ–² 3.2%
ytdβ–² 68.5%
1yβ–² 71.9%
🏦Market Cap
$95M
Small Cap
πŸ“ˆRevenue Growth (YoY)
8.5%
Slowing
πŸ“ŠGross Margin
40.3%
Healthy
πŸ’΅FCF Margin
19.5%
Healthy
βš–οΈP/S Ratio
3.2x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$10.41 – $10.41
52-Week Range
$4.52 – $12.10
Volume (shares)
1,600
Avg Volume (shares)
β€”
Shares Outstanding
9.1M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$28M
Last Q Revenue
$7M
P/E Ratio
122.8
P/S Ratio
3.2x
EPS (TTM)
$0.08
Dividend Yield
β€”
Dilution (1yr)
+1.2%
ICCC logo

IMMUCELL CORP

ICCC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$28Mβ–² +4.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
41.4%β–² +38.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2Mβ–Ό βˆ’200.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1Mβ–Ό βˆ’1236.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.0Mβ–² +1.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$9Mβ–² +$2M YoY
StockOtter Β· stockotter.space

About IMMUCELL CORP

ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.